Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A French Study to Evaluate the Usefulness of an Implantable Continuous Glucose Monitoring (CGM) Sensor to Improve Glycemic Control in Participants With Diabetes Mellitus
- Conditions
- Diabetes Mellitus
- Interventions
- Device: Eversense XL CGM SystemDevice: Usual SMBG or FGM device used by participants
- First Posted Date
- 2018-02-26
- Last Posted Date
- 2021-09-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 239
- Registration Number
- NCT03445065
- Locations
- 🇫🇷
CHU Amiens Picardie, Amiens, France
🇫🇷Hopital Hotel Dieu - Creusot, Le Creusot, France
🇫🇷CHRU de Lille, Lille, France
Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)
- First Posted Date
- 2018-02-23
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1053
- Registration Number
- NCT03444870
- Locations
- 🇺🇸
Bradenton Research Center, Bradenton, Florida, United States
🇺🇸Neurology Consultants of Dallas; Research Department, Dallas, Texas, United States
🇨🇦Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)
- First Posted Date
- 2018-02-23
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 975
- Registration Number
- NCT03443973
- Locations
- 🇺🇸
Irvine Center for Clinical Research, Irvine, California, United States
🇺🇸SUNY Upstate Medical University, Syracuse, New York, United States
🇺🇸Texas Neurology PA, Dallas, Texas, United States
A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- First Posted Date
- 2018-02-15
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 558
- Registration Number
- NCT03434379
- Locations
- 🇯🇵
Hokkaido University Hospital, Hokkaido, Japan
🇩🇪Campus Virchow-Klinikum Charité Centrum 13; Medizinische Klinik; Abt.Hepatologie u.Gastroenterologie, Berlin, Germany
🇨🇦Jewish General Hospital, Montreal, Quebec, Canada
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
- Conditions
- Metastatic Breast Cancer
- Interventions
- Drug: Chemotherapy (Gemcitabine + Carboplatin or Eribulin)
- First Posted Date
- 2018-02-06
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 580
- Registration Number
- NCT03424005
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸University of California San Diego Medical Center, La Jolla, California, United States
🇺🇸Stanford Cancer Institute, Stanford, California, United States
A Study to Investigate The Effectiveness Of Atezolizumab In Patients With Inoperable Locally-Advanced Or Metastatic Urothelial Carcinoma Of The Urinary Tract (Announce)
- Conditions
- Urothelial Carcinoma
- First Posted Date
- 2018-01-16
- Last Posted Date
- 2019-04-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 22
- Registration Number
- NCT03399643
- Locations
- 🇩🇪
Urologische Praxis Dr. Krieger, Chemnitz, Germany
🇩🇪Praxis Dr.med. Wolfgang Hölzer, Berlin, Germany
🇩🇪Zeisigwaldkliniken Bethanien, Chemnitz, Germany
Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors
- Conditions
- Advanced/Metastatic Head and Neck, Oesophageal and Cervical Cancers
- Interventions
- First Posted Date
- 2017-12-29
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 256
- Registration Number
- NCT03386721
- Locations
- 🇫🇷
ICM; Medecine B3, Montpellier cedex 5, France
🇬🇧Christie Hospital Nhs Trust; Medical Oncology, Manchester, United Kingdom
🇹🇷Adana Baskent University Hospital; Medical Oncology, Adana, Turkey
A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Emicizumab in Healthy Chinese Volunteers
- First Posted Date
- 2017-12-21
- Last Posted Date
- 2019-09-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 16
- Registration Number
- NCT03380780
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, China
Observational Study to Monitor Safety and Effectiveness of Obinutuzumab in Follicular Lymphoma or Previously Untreated Chronic Lymphocytic Leukemia
- Conditions
- Chronic Lymphocytic LeukemiaFollicular Lymphoma
- Interventions
- Biological: obinutuzumab
- First Posted Date
- 2017-12-15
- Last Posted Date
- 2023-01-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 55
- Registration Number
- NCT03374137
- Locations
- 🇰🇷
Gachon University Gil Medical Center, Incheon, Korea, Republic of
🇰🇷Pusan National University Hospital, Busan, Korea, Republic of
🇰🇷Hallym University Sacred Heart Hospital; Department of Hematology, Gyeonggi-do, Korea, Republic of
A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer
- Conditions
- Triple Negative Breast Neoplasms
- Interventions
- First Posted Date
- 2017-12-13
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 595
- Registration Number
- NCT03371017
- Locations
- 🇩🇪
Klinikum Essen-Mitte Ev. Huyssens-Stiftung / Knappschafts GmbH; Klinik für Senologie / Brustzentrum, Essen, Germany
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
🇦🇷Fundación CENIT para la Investigación en Neurociencias, Buenos Aires, Argentina